NewAmsterdam Pharma announced that late-breaking data from its pivotal Phase 3 BROADWAY and TANDEM studies were presented at the European Atherosclerosis Society (EAS) Congress 2025. Simultaneously, these data were published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM), providing significant peer-reviewed validation.
The Phase 3 data confirmed that obicetrapib, as an adjunct to statins, reduced LDL-C by 35% as monotherapy and by 50% in combination with ezetimibe. The BROADWAY trial also showed a 21% observed reduction in major adverse cardiovascular events (HR=0.79, CI 0.54-1.15), reinforcing the drug's potential cardiovascular benefits.
Pooled Phase 3 data across BROADWAY, TANDEM, and BROOKLYN trials demonstrated median placebo-adjusted Lp(a) reductions of 45% for patients with baseline levels ranging from 50-150 nmol/L. This broad impact on multiple cardiovascular risk factors, coupled with a safety profile comparable to placebo, supports obicetrapib's potential as a foundational therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.